Raj Vuppalanchi

Dec 28, 2023 | onlinelibrary.wiley.com | Raj Vuppalanchi |Kris V. Kowdley

Individuals with primary biliary cholangitis (PBC) are at risk of progressive liver disease with extra-hepatic symptoms that can significantly diminish health-related quality of life.1, 2 Ursodeoxycholic acid (UDCA) is the first-line agent for treating PBC.1, 2 Obeticholic acid (OCA) was approved in 2016 as a second-line treatment using improvement in alkaline phosphatase (ALP) and bilirubin as surrogate endpoints for accelerated approval using the ‘sub-part H’ pathway.3 Although reduction in...